PCRXPacira BioSciences, Inc.
Price
+55%1YEnd-of-day closes, not the intraday tick.
More going right than wrong
Quality mixed, nothing alarming, price roughly fair, growth steady, the market with it.
Charts
As reported to the SEC, without any scoring.
Pacira BioSciences, Inc. (PCRX) reported revenue of $192M in Q2 2026 (quarter ended Jun 30, 2026), up 6.2% from the same quarter a year earlier. That came with a gross margin of 77% and net income of $4.7M (2.4% of revenue). For the full year FY2025, revenue was $726M (+3.6% year on year) and net income $7.0M. The next results filing is expected around Nov 5, 2026, the same week as a year ago.
What the company said
The company's own words from its current reports to the SEC, newest first
- Oct 8, 2026On October 8, 2026, Pacira BioSciences, Inc., a Delaware corporation (the “Company” or “Pacira”), entered into an Agreement and Plan of Merger (the “Merger Agreement”) with Viatris Inc., a Delaware corporation (“Parent”), and Peach Purchaser Sub Inc., a Delaware corporation and wholly owned subsidiary of Parent …Material agreement entered · Form 8-K
- Aug 4, 2026Pacira BioSciences Reports Second Quarter 2026 Financial Results.Earnings release · press release
- Jun 30, 2026On June 28, 2026, Pacira BioSciences, Inc. (the “Company”) and Pacira CryoTech, Inc., the Company’s wholly owned subsidiary (the “Subsidiary”), entered into a Stock and Asset Purchase Agreement (the “Purchase Agreement”) with Zimmer, Inc. (the “Purchaser”), a subsidiary of Zimmer Biomet Holdings, Inc. (“Zimmer Biomet”)Material agreement entered · Form 8-K
Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.
Why these answers
Each answer with the checks it was read from. Open one for the numbers.
Conflicts between checks are named, never averaged, and thin data says so.
Drug Manufacturers, Specialty & Generic
Ranks #19 of 41 by RyuScore